 |
|
|
| |
SURVEYOR-I: 98% - 100% SVR4 in HCV Genotype 1 Non-Cirrhotic Treatment-Naïve or Pegylated Interferon/Ribavirin Null-Responders with the Combination of the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Fred Poordad,1 Franco Felizarta,2 Armen Asatryan,3 Tarek Hassanein,4 Humberto Aguilar,5 Jacob Lalezari,6 J. Scott Overcash,7 Teresa I. Ng,3 Ran Liu,3 Chih-Wei Lin,3 Federico J. Mensa,3 Jens Kort3
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2Private practice, Bakersfield, CA, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Southern California GI and Liver Centers and Southern California Research Center, Coronado, CA, USA; 5Louisiana Research Center, Shreveport, LA, USA; 6Quest Clinical Research, San Francisco, CA, USA; 7eStudySite, San Diego, CA, USA
|
| |
|
|
|
|
|
